Market Report, "Malaysia Pharmaceuticals & Healthcare Report Q4 2015", published

Malaysia's epidemiological profile will remain attractive to pharmaceutical companies as the country sees a rising burden of both communicable and non-communicable diseases. This commercial opportunity is further reinforced by the government's commitment to improve healthcare in its FY2015 budget. However, poor intellectual property protection and the implementation of a Goods and Service Tax continue dampen opportunities for innovative drugmakers.

Headline Expenditure Projections

Pharmaceuticals: MYR7.22bn (USD2.21bn) in 2014 to MYR7.88bn (USD1.97bn) in 2015; +9.2% in local currency and -10.7% in US dollar terms. Forecast in line with last quarter.
Healthcare: MYR42.62bn (USD13.02bn) in 2014 to MYR45.85bn (USD11.46bn) in 2015; +7.6% in local currency and -12.0% in US dollar terms. Forecast revised downwards from last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1044815_malaysia_pharmaceuticals.aspx?afid=301

Risk/Reward Index

Malaysia's Pharmaceutical Risk/Reward Index (RRI) score for Q415 is 58.9 out of 100, making it the eighth most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.

Key Trends And Developments

August

The prices of imported drugs might rise as a result of a weak Malaysian ringgit, according to Health Minister Subramaniam Sathasivam . However, the increase would not be permanent and the situation will not be limited to Malaysia - occurring in other countries as well as it is a global phenomenon, Subramaniam added. The minister assured that government hospitals and clinics will remain unaffected by the increase in drug costs.

The Malaysia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Malaysia, to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015